| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
YAP-TEAD-IN-2 directly targets the YAP-TEAD protein-protein interaction interface, which is a central node in the Hippo signaling pathway. By inhibiting this interaction with an IC50 of 2.7 nM, it prevents TEAD-mediated transcription of genes involved in cell proliferation, survival, and organ size control.
|
|---|---|
| ln Vitro |
YAP-TEAD-IN-2 exhibits potent inhibition of the YAP-TEAD PPI with a sub-nanomolar IC50 (2.7 nM) as determined in biochemical assays. It is anticipated to suppress the expression of YAP/TEAD target genes such as CTGF and CYR61 in cancer cells with hyperactive Hippo signaling.
|
| ln Vivo |
A detailed in vivo efficacy data for YAP-TEAD-IN-2 has not been reported in the literature. Based on its potent in vitro PPI inhibition, it is expected to show anti-tumor activity in animal models of cancers driven by YAP/TAZ hyperactivation, such as mesothelioma and certain types of NSCLC.
|
| Enzyme Assay |
A common YAP-TEAD PPI assay uses time-resolved fluorescence resonance energy transfer (TR-FRET) technology. Biotin-labeled TEAD protein and His-tagged YAP protein are incubated with increasing concentrations of YAP-TEAD-IN-2. After adding streptavidin-labeled donor and anti-His-labeled acceptor beads, the TR-FRET signal is measured to calculate the 2.7 nM IC50 value.
|
| Cell Assay |
For cellular assays, the NCI-H226 mesothelioma cell line (harboring NF2 mutation) or other YAP-addicted cancer cells are typically used. Cells are treated with YAP-TEAD-IN-2 at various concentrations for 24-48 hours. Target engagement is assessed by measuring mRNA expression of YAP/TEAD target genes (CTGF, CYR61) via qRT-PCR, and cell viability is assessed using CellTiter-Glo after 72-96 hours of treatment.
|
| Animal Protocol |
No animal model data has been reported for YAP-TEAD-IN-2.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic parameters (oral bioavailability, half-life, Cmax, AUC) for YAP-TEAD-IN-2 have not been reported.
|
| Toxicity/Toxicokinetics |
No specific toxicology data has been reported for YAP-TEAD-IN-2, as it is currently a preclinical research tool compound for studying the Hippo signaling pathway.
|
| References | |
| Additional Infomation |
YAP-TEAD-IN-2 is a potent inhibitor of the YAP-TEAD protein-protein interaction (IC50 = 2.7 nM). It has CAS number 2714432-83-2, molecular formula C25H24ClFN2O4, and molecular weight 470.92. This compound is a valuable chemical probe for dissecting Hippo signaling mechanisms in cancer biology and other diseases where this pathway is dysregulated.
|
| Molecular Formula |
C25H24CLFN2O4
|
|---|---|
| Molecular Weight |
470.920469284058
|
| Exact Mass |
470.14
|
| CAS # |
2714432-83-2
|
| PubChem CID |
157852210
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
33
|
| Complexity |
666
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COCCOC1=C(C(=C(C=C1)C(=O)N)C2=C(C=CC3=C2C[C@@](O3)(CN)C4=CC=CC=C4)Cl)F
|
| InChi Key |
DMOHFURXRRTVGP-RUZDIDTESA-N
|
| InChi Code |
InChI=1S/C25H24ClFN2O4/c1-31-11-12-32-20-9-7-16(24(29)30)22(23(20)27)21-17-13-25(14-28,15-5-3-2-4-6-15)33-19(17)10-8-18(21)26/h2-10H,11-14,28H2,1H3,(H2,29,30)/t25-/m1/s1
|
| Chemical Name |
2-[(2S)-2-(aminomethyl)-5-chloro-2-phenyl-3H-1-benzofuran-4-yl]-3-fluoro-4-(2-methoxyethoxy)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1235 mL | 10.6175 mL | 21.2350 mL | |
| 5 mM | 0.4247 mL | 2.1235 mL | 4.2470 mL | |
| 10 mM | 0.2124 mL | 1.0618 mL | 2.1235 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
